At xcube.bio, we believe every biopharma innovation deserves a clear path to patients.
We help agile biotech companies go beyond the R&D phase by rethinking market access — with smarter strategies, hands-on support, and a collaborative mindset.
Zug, Switzerland – June 3, 2026 – Xcubebio AG, a market entry acceleration engine for innovative biopharma and transformative therapeutics, today announced the appointments of Carinne Brouillon, Pascal Noth and Jaak Peeters to its Board of Directors, adding...
Eder Therapeutics, a Canadian biopharmaceutical company focused on rare genetic disorders and XCubeBio AG, a biotechnology platform company focused on accelerating successful international market entry for innovative therapeutics, today announced their intention to...
Eder Therapeutics and xcube.bio have announced a strategic cooperation to facilitate the market entry and commercialization of biotech assets in Canada and Europe. The two companies will coordinate their offerings to biopharma innovators in their respective regions...
